Abstract
ABSTRACT Aim: Triple negative breast cancer (TNBC), which represents approximately 15% of breast cancers, is defined by lack of expression of ER and PR, and lack of overexpression of HER2. Treatment options for TNBC are limited due to the lack of a clinically validated molecular target. Despite increased sensitivity to standard chemotherapy, TNBC is associated with a higher risk of relapse and poorer overall survival, than other breast cancer subtypes. The aim of this study was to profile chemotherapy-induced changes in TNBC cells, in order to identify new druggable targets that may enhance response to chemotherapy. Methods: Two TNBC cell lines, MDA-MB- 468 (cisplatin sensitive), and HCC-1143 (cisplatin resistant), were treated with cisplatin (2 µM) or docetaxel (2 nM) for 24 hours. Following treatment, proteomic profiling was performed using semi-quantitative label-free LC-MS-based proteomics analysis. Results: In cisplatin-treated HCC-1143 cells, 7 proteins with significantly (p 1.5 fold) were identified, 5 up-regulated and 2 down-regulated. In cisplatin-treated MDA-MB-468 cells, significant changes in 3 proteins were identified, with 2 increased and 1 decreased. Following docetaxel treatment, 43 altered proteins were identified in HCC1143 cells (32 increased, 11 decreased), and 3 proteins in MDA-MB-468 cells (1 increased, 2 decreased). Three proteins have been selected for further evaluation as potential targets to improve response to cisplatin and/or docetaxel. Neuroblast differentiation-associated protein (AHNAK), which has been implicated in activating PKC, is up-regulated in HCC1143 following treatment with both cisplatin (3.0-fold) and docetaxel (1.8-fold). Malate dehydrogenase (MDH2), which has been implicated in docetaxel resistance in prostate cancer, is up-regulated 2.2-fold, in docetaxel-treated HCC1143 cells. DNA-dependent protein kinase (DNA-PK) is up-regulated 1.6-fold in cisplatin-treated MDA-MB-468 cells. Previous studies suggest that DNA-PK plays a role in DNA repair following cisplatin treatment. Conclusions: In summary, we have identified three potential novel targets for TNBC which are druggable and may improve response to chemotherapy. Therapies targeting these three proteins will be evaluated, in combination with chemotherapy, in TNBC cell lines. Disclosure: J. Crown: Prof John Crown has received funding from Sanofi-Aventis and Bristol Myers Squibb for research and education activities. All other authors have declared no conflicts of interest.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
